Literature DB >> 21710488

The S. mansoni glycoprotein ω-1 induces Foxp3 expression in NOD mouse CD4⁺ T cells.

Paola Zaccone1, Oliver T Burton, Sarah E Gibbs, Nigel Miller, Frances M Jones, Gabriele Schramm, Helmut Haas, Michael J Doenhoff, David W Dunne, Anne Cooke.   

Abstract

Immunization with Schistosoma mansoni soluble antigen preparations protects non-obese diabetic (NOD) mice against the development of type 1 diabetes. These preparations have long been known to induce Th2 responses in vitro and in vivo. Recently, two separate groups have reported that ω-1, a well-characterized glycoprotein in S. mansoni soluble egg antigens (SEA), which with IL-4 inducing principle of S. mansoni eggs (IPSE/α-1) is one of the two major glycoproteins secreted by live eggs, is a major SEA component responsible for this effect. We found that ω-1 induces Foxp3 as well as IL-4 expression when injected in vivo. We confirmed that ω-1 conditions DCs to drive Th2 responses and further demonstrated that ω-1 induces Foxp3(+) T cells from NOD mouse naïve T cells. In contrast, IPSE/α-1 did not drive Foxp3 responses. The in vitro development of Foxp3-expressing T cells by ω-1 was TGF-β- and retinoic acid-dependent. Our work, therefore, identifies ω-1 as an important factor for the induction of Foxp3(+) T cells by SEA in NOD mice.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21710488     DOI: 10.1002/eji.201141429

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  40 in total

1.  Dendritic cells treated with crude Plasmodium berghei extracts acquire immune-modulatory properties and suppress the development of autoimmune neuroinflammation.

Authors:  Rodolfo Thomé; Luidy K Issayama; Thiago Alves da Costa; Rosária D Gangi; Isadora T Ferreira; Catarina Rapôso; Stefanie C P Lopes; Maria Alice da Cruz Höfling; Fábio T M Costa; Liana Verinaud
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

Review 2.  Therapeutic potential of helminths in autoimmune diseases: helminth-derived immune-regulators and immune balance.

Authors:  Meng Wang; Linxiang Wu; Rennan Weng; Weihong Zheng; Zhongdao Wu; Zhiyue Lv
Journal:  Parasitol Res       Date:  2017-06-29       Impact factor: 2.289

Review 3.  Helminth infection and type 1 diabetes.

Authors:  Paola Zaccone; Samuel W Hall
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 4.  A double edged sword: Schistosoma mansoni Sm29 regulates both Th1 and Th2 responses in inflammatory mucosal diseases.

Authors:  Sergio C Oliveira; Barbara C Figueiredo; Luciana S Cardoso; Edgar M Carvalho
Journal:  Mucosal Immunol       Date:  2016-08-24       Impact factor: 7.313

5.  Amelioration of type 1 diabetes by recombinant fructose-1,6-bisphosphate aldolase and cystatin derived from Schistosoma japonicum in a murine model.

Authors:  Ke Yan; Bo Wang; Huabang Zhou; Qingli Luo; Jilong Shen; Yunxia Xu; Zhengrong Zhong
Journal:  Parasitol Res       Date:  2019-12-16       Impact factor: 2.289

Review 6.  The Potential Role of Schistosome-Associated Factors as Therapeutic Modulators of the Immune System.

Authors:  Junhui Li; Hong Liu; Jie Jiang; Xingguo She; Ying Niu; Yingzi Ming
Journal:  Infect Immun       Date:  2020-07-21       Impact factor: 3.441

Review 7.  Leukocyte homing, fate, and function are controlled by retinoic acid.

Authors:  Yanxia Guo; Chrysothemis Brown; Carla Ortiz; Randolph J Noelle
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

Review 8.  Helminth infections and host immune regulation.

Authors:  Henry J McSorley; Rick M Maizels
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 9.  Th2 responses in schistosomiasis.

Authors:  Keke Fairfax; Marcia Nascimento; Stanley Ching-Cheng Huang; Bart Everts; Edward J Pearce
Journal:  Semin Immunopathol       Date:  2012-11-09       Impact factor: 9.623

Review 10.  Inflammasomes and Type 1 Diabetes.

Authors:  James Alexander Pearson; F Susan Wong; Li Wen
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.